Nothing lasts forever.
Nothing lasts forever especially in the world of drug development welcome back to the program you beautiful people my name is dr dan i’m a pharmacist and obesity expert and today we’re going to talk about whether ozempic slash vogovi is still the king of the hill is it still the end-all be-all when it comes to weight management or is there a new medication that is
Going to come and knock this king off of its hill but before we dive into that don’t forget to hit the subscribe button down below and check me out on my other channels at the official dr dan i’m on the tick the talk the gram the book you name it we are out there and i post content there daily and of course if you need some additional support check out my website
Healthcareevolve.ca and you can book a free consult with myself to see if you’d be a good fit for our program to work with me and my team in helping you with your weight management goals now it seems like just yesterday when we govi was approved for weight management and i mean here in canada it kind of was just yesterday back in november of 2021 we are just starting
2022 so it really wasn’t that long ago that legovia officially got the indication for weight management and as a bit of a refresher for you well govi is ozempic so they both have the same molecule within them called semiglutid ozempic is only indicated for diabetes management though up to a maximum dose of one milligram once per week and we govi is indicated for
Obesity management up to a maximum dose of 2.4 milligrams once per week and up to this point wagovey has been the reigning king on the drug market in terms of weight management if you recall from some of my previous videos i reviewed the step trials and what they ultimately found there was that individuals that took wilgovie at a dose of 2.4 milligrams once per
Week over half of the individuals lost 15 percent or more of their baseline body weight and up to one third of the individuals lost greater than 20 percent of their baseline body weight now 20 weight loss that is on the level of what we see with bariatric surgery let alone a medication so that’s really really really cool but today we’re going to talk about one
Of the competitor drugs that are potentially going to be coming out in the near future here that might show ozempic or bugovi is no longer at the top so a new medication from the drug company eli lilly called trizepatide will likely be getting fda approval in 2022 for diabetes management and shortly there afterwards i suspect they’re going to get the approval
For obesity management too and thus far in the clinical trials that have been done triseptite has shown some really impressive results in fact today we’re going to review the results from the surpass 2 trial and in the surpass 2 trial what the investigators actually did is they compared trizapatide to ozempic in diabetes management and of course they looked at
Weight loss as an additional outcome but before we dive into that what exactly is trizepatite so triseptide really isn’t too different from ozempic in that it is a glp1 receptor agonist so it binds to the glp1 receptors within the human body but it also has another component to it called gip and gip is another hormone that is naturally produced by the human body
And this is called glucose dependent insulin tropic polypeptide i get that right yes yes i did that was a that was a big big big word for a small acronym there now i’m not going to get into the complexities of what gipp does and when it doesn’t work because there’s a lot of stuff that’s going on there and some of it we don’t exactly know but in a lot of ways it
Acts similar to glp1 it seems to have a synergistic effect when the glp-1 and the gip are combined together in not only managing your blood sugar levels but also it seems to act in similar areas of the brain when it comes to weight management so it’s decreasing that want and drive for food so in the surpass 2 trial frias and friends basically did a randomized
Controlled non-inferiority trial now i won’t get into the details around that but essentially what they wanted to show was that triseptide was essentially no worse or didn’t suck any more than ozempic they were basically comparable and maybe try to show that one was superior to the other and what they did in this trial is they had four groups of individuals they
Had three groups that got varying doses of trisepitide anywhere from 5 10 and 15 milligrams once a week compared to ozempic at a dose of one milligram once per week now as you can see from these graphs right here was that every single dose of trizepatite was more effective than ozempic one milligram in reducing blood sugar levels and just to give you a few of the
Finer details here the average starting a1c was about point three percent and what trisepite fifteen milligrams once per week ultimately did is it brought that a1c down to about five point eight percent on average and ozempic one milligram only brought the a1c down to six point four on average and this was over a 40-week period and what they also found is that the
Higher the starting a1c the greater the drop that they ultimately found now what about weight loss and as you can see from this graph right here is that all three doses of trisepitide blew the ozempic one milligram dose out of the water in terms of weight loss in this style with individuals that were taking the trizepatite of 15 milligrams once per week losing on
Average about 13.1 percent of their baseline body weight i know that is effing wild so obviously triseptide did not suck compared to ozampic one milligram or semiglutid one milligram once per week and yes we didn’t do the comparison against the wagovie dose of 2.4 milligrams once per week and in the bugovi trials there was a greater weight loss of 15 percent to
20 percent that was ultimately seen but based on this if we were to increase the dose of trizepatite if that can be done safely triseptite is obviously probably going to be more effective than wilgovie in lowering weight even further so obviously triceptide at all three doses definitely did not suck compared to ozempic in fact it was more effective than ozempic
One milligram once per week not only in blood sugar management but also in weight loss now ozempic or semiglutid is only approved for diabetes management up to a maximum dose of one milligram once per week semiglutid or wagovi 2.4 milligrams once per week is the dose that we use for obesity management and that is the dose that we saw that 15 on average reduction
In baseline body weight and upwards of 20 percent of one-third of participants from baseline body weight in that group so the big question is will triseptide be studied at a higher dose can it be used safely at a higher dose that’s really the big question because if we can use an increased triceptide beyond this 15 milligrams once per week what we’re ultimately
Likely going to see is that it overall is more effective than even wagovi at 2.4 milligrams once per week but in this trial here they only compared it to the semiglutid wilgovie ozempic dosing of one milligram once per week and as we speak right now the weight loss trials are currently underway so we should likely have this data in the very near future in which it
Will show whether triseptite is indeed more effective and whether we can safely use it at a higher dose when compared to a govi 2.4 milligrams once per week but the weight loss trials are currently underway and we should have the data soon to say whether triseptite is indeed more effective and can be safely used at a higher dose compared to legovie now a couple
Things that i do want to note here and kind of does ring some bells or alarms if you will in terms of the safety of this medication is that a lot more individuals in the trisepitide groups did experience more severe or serious adverse events compared to the ozampa group as well almost double the number of individuals on the triseptide 15 milligrams once per week
Dropped out of the trial due to the drug side effects compared to the ozempic one milligram once per week so overall the drug definitely seems to have a greater number of side effects which ultimately happens when we have a drug that is more potent so it’s going to be a matter of yeah whether it’s going to be safe to increase that dose higher to get more weight
Loss benefits that’s going to be a real question for the future so there you have it folks overall this trial was relatively well done there was obviously a few flaws as with any study but it was a pretty standard randomized controlled non-inferiority trial that really did show some above average results when it came to triceptide and i would definitely argue that
Trisepitide is going to give ozempic slash fugovi a pretty good run for its money when it hits the market and as an fyi trizepatite is probably going to be the first of many medications within this class that are going to be coming to market here in the very near future so ozempic and bugovi’s reign overall is probably coming to an end sooner than later i will of
Course let you know and provide you the details when those trials come out and in the meantime don’t forget to hit that subscribe button down below as well check me out on my other channels at the official dr dan i’m on the tick the talk the book you name it we are out there as well check out our website healthcareevolv.ca where you can book a consult with myself
And work with myself and my team if you’re a good fit for our program and as always you beautiful people always remember that small tweaks lead to massive peaks until next time you
Transcribed from video
New Obesity meds? Could Ozempic or Wegovy no longer be the King of the Hill? By Dr. Dan – Weight-loss via Habit MasteryliveBroadcastDetails{isLiveNowfalsestartTimestamp2022-01-31T200010+0000endTimestamp2022-01-31T201157+0000}